Published
Monitor patients for hypersensitivity reactions during and after zolbetuximab infusion based on first/subsequent infusion and ≥ Grade 2 adverse event occurrence
  • Monitor patients during and after each zolbetuximab infusion for hypersensitivity reactions with signs and symptoms that are highly suggestive of anaphylaxis (e.g., urticaria, repetitive cough, wheeze, and throat tightness/change in voice).1
    • Post-infusion monitoring period is at least two hours after the first infusion. For subsequent infusions, monitor approximately two hours if Grade ≥ 2 adverse events (AE) were observed during the first infusion or post-infusion monitoring period, or at least one hour in their absence (Table 1).
  • Monitoring is also recommended for patients for signs and symptoms of infusion related reactions including nausea, vomiting, abdominal pain, salivary hypersecretion, pyrexia, chest discomfort, chills, back pain, cough, and hypertension.1

Table 1. Zolbetuximab post-infusion monitoring periods1

Infusion

Clinical circumstance

Post-infusion monitoring perioda

First infusion

All patients

At least two hours after completion

Subsequent infusions

Grade ≥ 2 AEs observed during the first infusion or post-infusion monitoring period

Approximately two hours after completion

Subsequent infusions

No Grade ≥ 2 AEs during the first infusion or post-infusion monitoring period

At least one hour after completion

AE: adverse event

aThe post-infusion monitoring period may be extended if clinically indicated, based on physician clinical judgment.

  • In the Phase 3 clinical trials SPOTLIGHT and GLOW, patients were observed for two hours following the first zolbetuximab/placebo infusion (Cycle 1 Day 1).2,3 Subsequent observation duration was determined by the occurrence of Grade ≥ 2 AEs.
  • Fluoropyrimidine- and platinum-containing chemotherapy may be initiated during the post-infusion monitoring period.1

  1. Data on File.

  2. Shitara K, Lordick F, Bang YJ, et al. Supplement to: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. Available at: https://doi.org/10.1016/s0140-6736(23)00620-7.

  3. Shah MA, Shitara K, Ajani JA, et al. Supplement to: Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 2023;29(8):2133-2141. Available at: https://doi.org/10.1038/s41591-023-02465-7.

If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:

Connect with Field Medical

Connect with Field Medical

Medical Science Liaisons (MSLs) and Medical Value and Access (MV&A) team members are available to help answer your scientific and health economic questions.

 

Submit an Inquiry

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

Hours: M–F, 8 AM–4:30 PM (CT)

Report an Adverse Event or Product Complaint

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)